现代中西医结合杂志2024,Vol.33Issue(13) :1782-1787,1793.DOI:10.3969/j.issn.1008-8849.2024.13.006

健脾为主的中药干预对KRAS突变型Ⅱ~Ⅲ期结直肠癌患者预后的影响

Effect of traditional Chinese medical treatment mainly for tonifying spleen on the prognosis of patients with stage Ⅱ-Ⅲ colorectal cancer of KRAS mutant

汤紫怡 孟丹 仇奕文 朱莹杰
现代中西医结合杂志2024,Vol.33Issue(13) :1782-1787,1793.DOI:10.3969/j.issn.1008-8849.2024.13.006

健脾为主的中药干预对KRAS突变型Ⅱ~Ⅲ期结直肠癌患者预后的影响

Effect of traditional Chinese medical treatment mainly for tonifying spleen on the prognosis of patients with stage Ⅱ-Ⅲ colorectal cancer of KRAS mutant

汤紫怡 1孟丹 1仇奕文 1朱莹杰1
扫码查看

作者信息

  • 1. 上海中医药大学附属龙华医院,上海 200032
  • 折叠

摘要

目的 观察以健脾为主的中药治疗对KRAS突变型Ⅱ~Ⅲ期结直肠癌患者预后的影响.方法 采用回顾性非随机同期对照研究方法,收集2015年1月-2021年12月就诊于上海中医药大学附属龙华医院、复旦大学肿瘤医院闵行分院的116例KRAS突变型Ⅱ~Ⅲ期结直肠癌患者资料,以持续接受中药治疗≥3个月的患者为治疗组,以未接受中药规范治疗或持续时间<3个月的患者为对照组.比较2组患者的中位无病生存期(采用Kaplan-Meier法计算)及1,2,3,5年无病生存率,分析影响患者无病生存期的危险因素.结果 治疗组中位无病生存期为23.13个月,较对照组的16.90个月明显延长(P<0.05);治疗组1,2,3,5年无病生存率分别为83%,46%,40%,30%,对照组分别为67%,38%,18%,6%,治疗组无病生存率明显高于对照组(P<0.05).中药治疗为患者无病生存期的独立保护因素(P<0.05),脉管内癌栓是患者复发转移的独立危险因素(P<0.05),淋巴结分期为N1期的患者相比于N2期患者复发转移的风险更低(P<0.05).结论 健脾为主的中药治疗可有效延长KRAS突变型Ⅱ~Ⅲ期结直肠癌患者的无病生存期,降低复发转移率;脉管内癌栓及区域淋巴结是KRAS突变型Ⅱ~Ⅲ期结直肠癌患者复发转移的高危因素.

Abstract

Objective It is to observe the effect of traditional Chinese medical treatment mainly for tonifying spleen on the prognosis of patients with stage Ⅱ-Ⅲ colorectal cancer of KRAS mutant.Methods A retrospective non-randomized con-temporaneous controlled study was conducted to collect data of 116 patients with stage Ⅱ-Ⅲ colorectal cancer of KRAS mu-tant treated in Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Minhang Branch of Cancer Hospital of Fudan University from January 2015 to December 2021,and those who had continuously treated with tra-ditional Chinese medicine for ≥3 months were regarded as the treatment group,and those who had not received standard-ized traditional Chinese medicine treatment or the duration was<3 months were regarded as the control group.The median disease-free survival(calculated by the Kaplan-Meier method)and the 1-,2-,3-,and 5-year disease-free survival rates of the patients were compared between the two groups,and the risk factors affecting the disease-free survival of the patients were analyzed.Results The median disease-free survival of the treatment group was 23.13 months,which was significantly longer than that 16.90 months of the control group(P<0.05);the 1-,2-,3-,and 5-year disease-free survival rates of the treatment group were 83%,46%,40%,and 30%,respectively,those of the control group were 67%,38%,18%,and 6%respectively,and the disease-free survival rates of the treatment group were significantly higher than those of the control group(all P<0.05).Traditional Chinese medicine treatment was an independent protective factor for the disease-free sur-vival(P<0.05),and intravascular cancer thrombus was an independent risk factor for the recurrent metastasis of the pa-tients(P<0.05),and the patients with lymph node stage N1 had a lower risk of recurrent metastasis compared with the patients with stage N2(P<0.05).Conclusion Traditional Chinese medical treatment mainly for tonifying spleen can ef-fectively prolong the disease-free survival and reduce the recurrence and metastasis rates of patients with stage Ⅱ-Ⅲ color-ectal cancer of KRAS mutant;intravascular thrombus and regional lymph nodes are the high-risk factors for recurrence and metastasis in patients with stage Ⅱ-Ⅲ colorectal cancer of KRAS mutant.

关键词

健脾中药/KRAS突变/结直肠癌/无病生存期

Key words

traditional Chinese medical treatment for tonifying spleen/KRAS mutation/colorectal cancer/disease-free survival

引用本文复制引用

基金项目

上海市中医肿瘤临床医学研究中心建设项目(21MC1930500)

上海市临床重点专科建设项目(中医肿瘤)(shslczdzk03701)

出版年

2024
现代中西医结合杂志
中国中西医结合学会河北分会,中华中医药学会

现代中西医结合杂志

CSTPCD
影响因子:1.775
ISSN:1008-8849
段落导航相关论文